Stanford Cancer Institute Directory
Lymphoma & Leukemia Profiles
Showing 11 - 20 of 23
Associate Professor of Pediatrics (Hematology and Oncology) at the Lucile Salter Packard Children's Hospital
Associate Professor of Medicine (Hematology)
Dr. Ravi Majeti is an Associate Professor in the Department of Medicine, Division of Hematology, and Institute for Stem Cell Biology and Regenerative Medicine at Stanford University. He was an undergraduate at Harvard, earned his MD and PhD from UCSF, and trained in Internal Medicine at Brigham and Women’s Hospital in Boston. Dr. Majeti completed his Hematology Fellowship at Stanford, and is a board-certified hematologist. While at Stanford, he completed post-doctoral training in the laboratory of Irving Weissman, where he investigated early human blood stem cell development and characterized acute myeloid leukemia (AML) stem cells. Dr. Majeti established his independent laboratory in 2009 with research focused on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly acute myeloid leukemia (AML). Dr. Majeti is a recipient of the Burroughs Wellcome Fund Career Award for Medical Scientists and is a New York Stem Cell Foundation Robertson Investigator.
Associate Professor of Medicine (Hematology) at the Stanford University Medical Center
Bruno C. Medeiros, MD is associate professor of medicine and director of the inpatient hematology service. He is also director of Cancer Center ITA services at Stanford Comprehensive Cancer Center. Dr. Medeiros graduated from the Universidade Federal do Parana with a medical degree, in 1998. He completed his post-graduate training at the University of Colorado in Denver and the Princess Margaret Hospital in Toronto (Acute leukemia fellowship). Dr. Medeiros’ clinical interests include management of advanced hematologic malignancies, including AML, ALL, MDS and CML. His clinical research interest focuses on the development of novel therapeutic regimens for patients with acute leukemia, with special interest in the development of novel therapeutic strategies for patients with acute myeloid leukemia. He is the leader in several institutional investigator initiated clinical trials, active investigator in collaborative multi-institutional clinical studies and an active member of the SWOG acute leukemia panel. Dr. Medeiros has authored more than 120 peer-reviewed manuscripts. Dr. Medeiros has served as the track leader for ASCO meeting Leukemia, Myelodysplasia and Transplantation scientific review subcommittee, he functions as the Associate Editor of the Leukemia Panel for Cancer.Net, he is a member of the editorial board for Leukemia Research and serves as a reviewer for several specialized journals, such as Blood, Leukemia, Haematologica and Cancer, among others.
George E. Becker Professor in Medicine and Professor, by courtesy, of Chemical and Systems Biology
Professor of Pathology at Stanford University Medical Center
Dr. Natkunam is an expert in the diagnosis of hematopoietic tumors including lymphoma and leukemia, and has over 15-years of experience. As the Director of Hematopathology, she oversees all hematopathology diagnostic services for Stanford Health and Stanford Children’s Health. Her research focuses on refining criteria for the diagnosis of hematopoietic tumors through discovery and application of biomarkers, an approach that has furnished novel reagents and guidelines for clinical practice. She currently serves on the editorial boards of the American Journal of Surgical Pathology and Human Pathology, and on the Eastern Cooperative Oncology Group and the Lunenburg Lymphoma Biomarker Consortium.
Rachford and Carlota Harris Professor
Dr. Nolan is the Rachford and Carlota A. Harris Professor in the Department of Microbiology and Immunology at Stanford University School of Medicine. He trained with Leonard Herzenberg (for his Ph.D.) and Nobelist Dr. David Baltimore (for postdoctoral work for the first cloning/characterization of NF-κB p65/ RelA and the development of rapid retroviral production systems). He has published over 180 research articles and is the holder of 20 US patents, and has been honored as one of the top 25 inventors at Stanford University. Dr. Nolan is the first recipient of the Teal Innovator Award (2012) from the Department of Defense (a $3.3 million grant for advanced studies in ovarian cancer), the first recipient of an FDA BAAA, for “Bio-agent protection” grant, $3million, from the FDA for a “Cross-Species Immune System Reference”, and received the award for “Outstanding Research Achievement in 2011” from the Nature Publishing Group for his development of CyTOF applications in the immune system. Dr. Nolan has new efforts in the study of Ebola, having developed instrument platforms to deploy in the field in Africa to study Ebola samples safely with the need to transport them to overseas labs (funded by a new $3.5 million grant from the FDA). Dr. Nolan is an outspoken proponent of translating public investment in basic research to serve public welfare. Dr. Nolan was the founder of Rigel Inc. (NASDAQ: RIGL), and Nodality, Inc. (a diagnostics development company), BINA (a genomics computational infrastructure company sold to Roche Diagnostics), and serves on the Boards of Directors of several companies as well as consults for other biotechnology companies. DVS Sciences, on which he was Chair of the Scientific Advisory Board, recently sold to Fluidigm for $207 million dollars (2014) on an investment of $14 million. His areas of research include hematopoiesis, cancer and leukemia, autoimmunity and inflammation, and computational approaches for network and systems immunology. Dr. Nolan’s recent efforts are focused on a single cell analysis advance using a mass spectrometry-flow cytometry hybrid device, the so- call “CyTOF” and the “Multiparameter Ion Beam Imager” (MIBI) developed by Dr. Mike Angelo in his lab (Dr. Angelo is now an Assistant Professor in the Dept of Pathology at Stanford). The approaches uses an advanced ion plasma source to determine the levels of tagged reagents bound to cells—enabling a vast increase in the number of parameters that can be measured per cell—either as flow cytometry devices (CyTOF) or imaging platforms for cancer (MIBI). Further efforts are being develop with another imaging platform terms CODEX that inexpensively converts fluorescence scopes to high dimensional imaging platforms. Dr. Nolan’s efforts are to enable a deeper understanding not only of normal immune function, trauma, pathogen infection, and other inflammatory events but also detailed substructures of leukemias and solid cancers—which will enable wholly new understandings that will enable better management of disease and clinical outcomes.
Professor of Radiology (General Radiology), of Biomedical Data Science and, by courtesy, of Management Science and Engineering